Abstract P1-12-02: Results of a phase 2, multicenter, single-arm study of eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer

Mapping Intimacies ◽

10.1158/0008-5472.sabcs12-p1-12-02 ◽

2012 ◽

Author(s):

L Vahdat ◽

L Schwartzberg ◽

S Glück ◽

J Rege ◽

J Liao ◽

...

Keyword(s):

Breast Cancer ◽

Phase 2 ◽

Eribulin Mesylate ◽

First Line Therapy ◽

Line Therapy ◽

Locally Recurrent

Download Full-text

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-014-2923-9 ◽

2014 ◽

Vol 146 (2) ◽

pp. 321-328 ◽

Author(s):

Kristi McIntyre ◽

Joyce O’Shaughnessy ◽

Lee Schwartzberg ◽

Stefan Glück ◽

Erhan Berrak ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor Receptor ◽

Phase 2 ◽

Eribulin Mesylate ◽

First Line Therapy ◽

Line Therapy ◽

Phase 2 Study ◽

Epidermal Growth ◽

Locally Recurrent

Download Full-text

Abstract P3-13-05: Eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer: Results of a phase 2, multicenter, single-arm study

10.1158/0008-5472.sabcs13-p3-13-05 ◽

2013 ◽

Author(s):

K McIntyre ◽

J O'Shaughnessy ◽

L Schwartzberg ◽

S Glück ◽

E Berrak ◽

...

Keyword(s):

Breast Cancer ◽

Phase 2 ◽

Eribulin Mesylate ◽

First Line Therapy ◽

Line Therapy ◽

Locally Recurrent

Download Full-text

Abstract P5-17-03: Quality of life results from a phase 2, multicenter, single-arm study of eribulin mesylate plus trastuzumab as first-line therapy for locally recurrent or metastatic HER2+ breast cancer

10.1158/1538-7445.sabcs14-p5-17-03 ◽

2015 ◽

Author(s):

Lee Schwartzberg ◽

Sharon Wilks ◽

Shannon Puhalla ◽

Joyce O'Shaughnessy ◽

Erhan Berrak ◽

...

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Phase 2 ◽

Eribulin Mesylate ◽

First Line Therapy ◽

Her2 Breast Cancer ◽

Line Therapy ◽

Locally Recurrent

Download Full-text

Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-014-3010-y ◽

2014 ◽

Vol 146 (2) ◽

pp. 329-329 ◽

Author(s):

Kristi McIntyre ◽

Joyce O’Shaughnessy ◽

Lee Schwartzberg ◽

Stefan Glück ◽

Erhan Berrak ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor Receptor ◽

Phase 2 ◽

Eribulin Mesylate ◽

First Line Therapy ◽

Line Therapy ◽

Phase 2 Study ◽

Epidermal Growth ◽

Locally Recurrent

Download Full-text

Abstract P4-12-12: Phase 2, multicenter, single-arm study of eribulin mesylate + trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer

10.1158/0008-5472.sabcs13-p4-12-12 ◽

2013 ◽

Author(s):

S Wilks ◽

S Puhalla ◽

J O'Shaughnessy ◽

L Schwartzberg ◽

E Berrak ◽

...

Keyword(s):

Breast Cancer ◽

Phase 2 ◽

Her2 Positive ◽

Eribulin Mesylate ◽

Her2 Positive Breast Cancer ◽

First Line Therapy ◽

Line Therapy ◽

Locally Recurrent ◽

Positive Breast Cancer

Download Full-text

Abstract P5-20-04: Eribulin mesylate + trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer: results from a phase 2, multicenter, single-arm study

10.1158/0008-5472.sabcs12-p5-20-04 ◽

2012 ◽

Author(s):

L Vahdat ◽

L Schwartzberg ◽

S Wilks ◽

J Rege ◽

J Liao ◽

...

Keyword(s):

Breast Cancer ◽

Phase 2 ◽

Her2 Positive ◽

Eribulin Mesylate ◽

Her2 Positive Breast Cancer ◽

First Line Therapy ◽

Line Therapy ◽

Locally Recurrent ◽

Positive Breast Cancer

Download Full-text

Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2014.04.004 ◽

2014 ◽

Vol 14 (6) ◽

pp. 405-412 ◽

Author(s):

Sharon Wilks ◽

Shannon Puhalla ◽

Joyce O'Shaughnessy ◽

Lee Schwartzberg ◽

Erhan Berrak ◽

...

Keyword(s):

Breast Cancer ◽

Phase 2 ◽

Her2 Positive ◽

Eribulin Mesylate ◽

Her2 Positive Breast Cancer ◽

First Line Therapy ◽

Line Therapy ◽

Locally Recurrent ◽

Positive Breast Cancer

Download Full-text

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study

10.1016/j.breast.2014.11.003 ◽

2015 ◽

Vol 24 (3) ◽

pp. 182-190 ◽

Author(s):

Véronique Diéras ◽

Hans Wildiers ◽

Jacek Jassem ◽

Luc Y. Dirix ◽

Jean-Paul Guastalla ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Randomized Study ◽

Metastatic Breast ◽

Phase 2 ◽

First Line Therapy ◽

Line Therapy ◽

Amg 386 ◽

Locally Recurrent

Download Full-text

1859 Clinical effects of prior chemotherapy on eribulin: Update and subgroup analysis of phase 2 multicenter single arm study of eribulin mesylate as first-line therapy for HER2 negative locally advanced or metastatic breast cancer

European Journal of Cancer ◽

10.1016/s0959-8049(16)30809-7 ◽

2015 ◽

Vol 51 ◽

pp. S285

Author(s):

S. Nishimura ◽

T. Takashima ◽

H. Kawajiri ◽

S. Kashiwagi ◽

S. Noda ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Clinical Effects ◽

Phase 2 ◽

Eribulin Mesylate ◽

Prior Chemotherapy ◽

First Line Therapy ◽

Download Full-text

Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator’s chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)

10.1055/s-0041-1730221 ◽

2021 ◽

Author(s):

A Schneeweiss ◽

D Miles ◽

E Ciruelos ◽

F Puglisi ◽

T Peretz-Yablonski ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Her2 Positive ◽

First Line Therapy ◽

Line Therapy ◽

Global Study ◽

Locally Recurrent

Download Full-text